
Licensed to fill prescriptions for patients in RI, MA, CT, NJ, NH, FL, ME and PA. New York patients are served on a limited basis while nonresident registration is pending.
Prepared to a veterinarian's order for one animal patient. Not FDA-approved.
Naltrexone is an FDA-approved animal drug for one narrow use. Animal Drugs@FDA lists a single product, Trexonil (NADA 141-074), and its federal regulation, 21 CFR 522.1465, covers use as an antagonist to carfentanil immobilization in free-ranging or confined elk and moose. Naltrexone tablets are also an approved human medicine for alcohol dependence and for blocking the effects of opioids. The Merck Veterinary Manual lists naltrexone, an opiate antagonist, among psychotropic drugs used in an extralabel manner for excessive self-licking conditions such as acral lick dermatitis in dogs and psychogenic alopecia in cats. Compounded preparations are not FDA-approved and are dispensed only on a veterinarian's prescription for an individual animal.
Naltrexone blocks the effects of opioid drugs. The human tablet label says it must not be given to patients receiving opioid pain medicines or dependent on opioids, that it can trigger a withdrawal reaction severe enough to require hospital care, and that trying to overcome the block with opioids may lead to a fatal overdose. Tell your veterinarian your animal takes naltrexone before any surgery, sedation or pain treatment. The human label also says to stop it if signs of acute hepatitis appear. The Trexonil regulation bars use in domestic food-producing animals. Ask your veterinarian or pharmacist about other medicines and supplements your animal takes.
Trexonil is approved only for elk and moose, so compounding naltrexone for other species from an approved product is extralabel use permitted under 21 CFR 530.13(b) only when no approved animal or human drug, used as labeled or in conformity with the extralabel criteria of part 530, will, in the available dosage form and concentration, appropriately treat the condition diagnosed; 530.13(a) excludes compounding from bulk. Naltrexone is not on FDA's GFI #256 office stock list; FDA lists naltrexone HCl as under review for horses and for several zoo and wildlife groups (updated 10/05/2026). FDA CVM's safety-related labeling change lists for 2022 to the present include no Trexonil change.
This formulation is compounded by Bayview Pharmacy on a prescriber's order for an individual patient. It is not an FDA-approved drug product, and the FDA has not evaluated it for safety, effectiveness, or manufacturing quality.
A valid prescription is required. Availability depends on Bayview's licensure in your state. This page is general information, not medical advice. Discuss your situation with a licensed healthcare provider.
This preparation is a controlled substance. Additional prescribing, refill, and shipping restrictions apply, and the states Bayview can dispense it to are narrower than for non-controlled preparations.
Search by NCPDP 4106882, or by name and ZIP: Bayview Pharmacy, Warwick, RI 02886. Select it as the destination pharmacy and save it as a favorite. Click any value to copy it.
Compounded preparations have no NDC, so this formula will not appear in your EHR's drug search. Use your system's compound, non-formulary, or free-text prescription entry and name the preparation exactly as written in step 3. If your EHR forces you to pick a listed drug, pick the closest entry for the active ingredient and put the full formula in the prescription body (the Sig or directions field), not in Notes to Pharmacy.
Compounded preparations have no NDC and will not appear in your drug search. For EPCS to validate, select a drug entry your EHR recognizes as controlled, usually the bulk powder entry for the active ingredient (for example Ketamine (bulk) powder, not a branded product), then put the full formula from step 3 in the prescription body. A free-text entry that does not validate as controlled will be rejected by your EPCS module.
Quantity and directions are starting points for this dose form, not treatment recommendations. Dosing remains the prescriber's responsibility.
Transmit from your EHR. For this non-controlled preparation we also accept fax to (401) 284-4506 and phoned orders at (401) 284-4505. Order forms are on the formulation pages and in the prescriber portal.
Transmit with two-factor authentication through your EPCS-enabled EHR. No order form is offered for this preparation; e-prescribing guides for our controlled preparations are on the formulation pages.
Licensed to dispense in RI, MA, CT, NJ, NH, FL, ME, and PA; New York is served on a limited basis while nonresident registration is pending. Compounded preparations are not FDA-approved. A valid prescription is required. Full guide, including steps by EHR: How to e-prescribe to Bayview. Questions about this formula: call (401) 284-4505.
Apply topically to affected area(s)